About Celyad

Bringing breakthrough pioneering therapies to patients with life-threatening diseases.

Celyad is a biopharmaceutical company, specialized in cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis. Our scientific approach is inspired by the natural mechanisms that are used by the body to fight disease.

Our key facts and figures


Technological platforms

2 technological platforms in immuno-oncology (autologous & allogeneic)


Study assets

3 study assets in pre-clinical and clinical development (CAR-T NKR-2,CAR-T NKR-3 and B7H6)


Phase I trial

1 phase I trial completed in the US for our CAR-T NKR-2 immuno-oncology program. No safety issue reported


Phase Ib trial

THINK trial initiated to evaluate safety and efficacy of CAR-T NKR-2 cells in 7 indications, both hematological (AML, MM) and solid malignancies (bladder, ovarian, breast, pancreas and colorectal)


International collaborations

4 international collaborations with Dartmouth College (USA), Institut Curie (France), ONO Pharmaceutical Co., Ltd (Japan), and Novartis (Switzerland)


Phase III trial

CHART-1, the European Phase III clinical trial evaluating the efficacy of C-Cure, our lead cardiology candidate, has been completed. Celyad is now looking for a partner to further develop and commercialize the product


of staff dedicated

84% of staff dedicated to R&D activities


Stock listings

3 stock listings on Euronext Brussels, Euronext Paris and NASDAQ